Expanded Access to ANG1005 for Individual Patients

NO_LONGER_AVAILABLE

Conditions studied: Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Breast Cancer With Recurrent Brain Metastases, Leptomeningeal Carcinomatosis

In brief

This is an expanded access study with ANG1005 treatment for two individual patients from Protocol ANG1005-CLN-03 with WHO Grade III Anaplastic Astrocytoma and WHO Grade III Anaplastic Oligodendroglioma and one individual patient from Protocol ANG1005-CLN-04 with Recurrent Brain Metastases and Leptomeningeal Carcinomatosis.

Key facts

Study ID

NCT02755987

Run by

Angiochem Inc

Last updated by the study team

2016-06-07

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Neurologically stable
• Karnofsky performance status (KPS) ≥ 80
• Adequate laboratory results

You may not qualify if…

• Radiotherapy within 3 months.
• Evidence of significant intracranial hemorrhage
• NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v4.0 Grade ≥ 2 neuropathy
• Inadequate bone marrow reserve
• Any evidence of severe or uncontrolled disease

Where it is running

• UC Irvine Health — Orange, California, United States
• Univeristy of Texas Health Science Center in San Antonio — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.